Structure Therapeutics reports positive topline data from phase 2 ACCESS II trial with once-daily oral small molecule GLP-1 receptor agonist, aleniglipron
doi: 10.3389/fcell.2025.1596421 Received 19 March 2025 Accepted 22 April 2025 Published 13 May 2025 Volume 13 - 2025 Edited by Matteo Avella, Sidra Medicine, Qatar Reviewed by Jurandy Penitente-Filho, JPF Consultoria, Brazil Qi Yin, Carnegie Institution for Science, United States Updates Copyright 2025 Gmez-Elas, Luque, Oscoz-Susino, Novero, Briski, Ksparas, Steeman, Stival, Lavolpe, Julianelli, Geller, Attie, Vassena, Krapf and Buffone
Compatibility with Other Ingredients One of the biggest practical differences between copper peptide types is what you can safely combine them with
Nature 563 , 354359 (2018)
3,7-bis(dimethylamino)-phenothiazin-5-ium Chloride Salt 186